ALX Oncology Holdings Inc $ALXO

By Microcap Ledger desk · CIK 0001810182

Facts as of Oct 11, 2026, 08:08 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange: Nasdaq Global Select Market
Sector: Pharmaceutical Preparations
Headquarters: South San Francisco, CA
Fiscal year end: December 31
Shares outstanding: 138,276,997 [10-Q 2026-08-06]
as of 2026-07-30

Sources: [10-K 2026-03-09]

What the company doesAI summary of filing

ALX Oncology is a clinical-stage biotechnology company developing cancer therapies. The company's lead product candidate, evorpacept, is a CD47-blocking fusion protein designed to be used in combination with other anti-cancer agents for multiple oncology indications including HER2-positive breast cancer, gastric cancer, multiple myeloma, and non-Hodgkin lymphoma. The company's second product candidate, ALX2004, is an EGFR-targeted antibody-drug conjugate that entered a Phase 1 clinical trial in August 2025. The company is pre-revenue and has funded operations through equity offerings and debt financing. [10-K 2026-03-09]

Segments: Evorpacept (CD47 blocker), ALX2004 (EGFR-targeted ADC)

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
6 months to Jun 2026	—	−$35.90M	−$34.70M	$22.69M	[10-Q 2026-08-06]
FY ended Dec 2025	—	−$101.69M	−$84.14M	$16.37M	[DEF 14A 2026-04-20]
FY ended Dec 2024	—	−$134.85M	−$121.91M	$17.57M	[DEF 14A 2026-04-20]

Quarterly cash burn: −$17.35M
Cash runway Estimate: ~3.9 months

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2024-10-31	52,743,104	[10-Q 2024-11-07]
2025-02-27	53,384,145	[10-K 2025-03-06]
2025-05-01	53,444,020	[10-Q 2025-05-08]
2025-08-05	53,551,134	[10-Q 2025-08-12]
2025-10-31	54,218,001	[10-Q 2025-11-07]
2026-03-02	131,608,278	[10-K 2026-03-09]
2026-05-01	134,562,917	[10-Q 2026-05-08]
2026-07-30	138,276,997	[10-Q 2026-08-06]

Shelf registration: S-3 filed 2025-03-06; declared effective 2025-04-24 [S-3 2025-03-06]

Listing status

Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-04-25. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

Date	Event	Details	Deadline	Filing
2025-04-25	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2025-04-25]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
Date	Insider	Type	Shares	Price	Filing
2026-08-17	Lettmann Jason	sell	2,230	$1.93	[4 2026-08-18]
2026-08-17	Wong Shelly	sell	573	$1.93	[4 2026-08-18]
2026-07-01	Wong Shelly	sell	1,404	$2.04	[4 2026-07-06]
2026-03-19	Lettmann Jason	sell	12,311	$2.17	[4 2026-03-23]
2026-03-19	Pinto Shelly	sell	903	$2.17	[4 2026-03-23]

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-08-14	13G/A	Beneficial ownership report (5%+ holder)
2026-08-06	10-Q	Quarterly report
2026-08-06	8-K	Results of operations
2026-07-27	13G	Beneficial ownership report (5%+ holder)
2026-06-30	8-K	Director or officer change; Regulation FD disclosure; Other events
2026-06-26	8-K	Material agreement entered; Material agreement terminated; New financial obligation
2026-06-11	8-K	Shareholder vote results
2026-05-27	13D/A	Beneficial ownership report (5%+ holder)
2026-05-15	13G/A	Beneficial ownership report (5%+ holder)
2026-05-15	13G/A	Beneficial ownership report (5%+ holder)
2026-05-08	10-Q	Quarterly report
2026-05-08	8-K	Results of operations

Facts as of Oct 11, 2026, 08:08 AM UTC. Small caps move fast; check the latest filings.